Policymakers must work with insurers and GLP-1 manufacturers to make sure these life-changing therapies remain accessible. Blanket denials of coverage will harm patients, invite long-term costs, and worsen the stigma we should be fighting against.
Policymakers must work with insurers and GLP-1 manufacturers to make sure these life-changing therapies remain accessible. Blanket denials of coverage will harm patients, invite long-term costs, and worsen the stigma we should be fighting against.
